NewsFeed Voices Science Insight Innovation
November, 2025
November 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
Amol Akhade: ALASCCA Trial – Aspirin as Precision Adjuvant in Colorectal Cancer?
Amol Akhade/LinkedIn
Oct 4, 2025, 12:27

Amol Akhade: ALASCCA Trial – Aspirin as Precision Adjuvant in Colorectal Cancer?

Amol Akhade, Senior Medical and Hemato-Oncologist at Fortis Hospital Mumbai and Founder of Suyog Cancer Clinics, shared a post on LinkedIn:

”NEJM 2025: ALASCCA Trial – Aspirin as Precision Adjuvant in Colorectal Cancer?

The ALASCCA trial (Martling et al., NEJM 2025) is a landmark step in repurposing a cheap, globally accessible drug — aspirin — within the framework of precision oncology.

Trial design:

  • 6,397 patients screened → 2,980 sequenced → 1,103 (37%) harbored PI3K-pathway alterations. Hotspot PIK3CA exon 9/20 mutations: 17% Other PI3K/PTEN/PIK3R1 variants: 20%
  • 626 randomized to aspirin 160 mg vs placebo for 3 years, double-blind, registry-based.

Results:

  • In hotspot (Group A): recurrence 7.7% vs 14.1% (HR 0.49, p=0.04). In other PI3K variants (Group B): recurrence 7.7% vs 16.8% (HR 0.42).
  • Disease-free survival trended positive, but overall survival benefit not shown yet

Number Needed to Treat (NNT):

  • Colon stage II → weak (NNT 42, ARD ~2%). Colon stage III → strong (NNT 9, ARD ~12%). Rectum stage III → best (NNT 6, ARD ~17–20%). Stage I/II rectum → modest, inconsistent benefit.

Safety:

  • Severe AEs: 16.8% with aspirin vs 11.6% with placebo. Most common: GI bleeding, thromboembolism, post-op complications. One aspirin-related death reported.

Critical view:

  • Strengths: biomarker-driven design, pragmatic registry-based RCT, global relevance of a low-cost intervention.

Limitations: borderline statistical significance (p=0.04 in Group A), wide confidence intervals, subgroup heterogeneity (sometimes non-hotspot mutations outperformed hotspots), and no OS benefit yet.

Clinical implication: Most compelling signal: stage III rectal & colon cancers. Stage II benefit marginal. Aspirin may join the armamentarium in high-risk, biomarker-selected subgroups, but universal use is premature.

Editorial take (Goldberg and Meyerhardt, NEJM):
They argue that biomarker-guided aspirin could mark long-awaited progress in adjuvant CRC therapy, similar to MSI-high immunotherapy (ATOMIC trial). But careful balancing of recurrence reduction vs bleeding risk is essential.

Bottom line:

  • The ALASCCA trial demonstrates the promise of repurposed, low-cost drugs guided by genomics. Aspirin halves recurrence in PI3K-altered CRC, but the benefit is heterogeneous and not yet practice-changing.

Future pooled analyses and replication will decide if aspirin truly becomes a standard precision adjuvant.”

ALASCCA Trial

Stay updated with Hemostasis Today.

ALASCCA Trial Amol Akhade Aspirin ATOMIC Trial colorectal cancer Health Hematology Hemostasis Today Medicine MSI-High Immunotherapy NEJM 2025 precision oncology
NewsFeed